Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
Journal of Virology · 2025
DOI: 10.1128/jvi.01034-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Shilei Ding und 26 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du CHUM, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR operating Pandemic and Health Emergencies Research, Division of Intramural Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, NIH HHS.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains a threat to human health, particularly among immunocompromised and elderly individuals, given their heightened vulnerability to coronavirus disease 2019 (COVID-19)-associated morbidity and mortality. Recently, omicron subvariants such as KP.3.1.1 and XEC have emerged with an enhanced ability to evade humoral immunity. The development of new strategies against these variants of concern remains an intense area of research. The small molecule VE607 is an entry inhibitor that targets the Spike glycoprotein and delays virus spread in vivo . To improve the potency of this new class of SARS-CoV-2 entry inhibitors, we generated and characterized VE607 analogs and identified candidates with enhanced activity against variants, including KP.3.1.1 and XEC. Promising analogs exhibited higher inhibitory potency than the original compound and stabilized the receptor-binding domain in its “up” conformation. Among these, DY-III-281 also reduced viral burden and delayed death in SARS-CoV-2-challenged K18-hACE2 transgenic mice. Furthermore, combining DY-III-281 with a non-neutralizing antibody engineered for Fc-enhanced functions exhibited an additive effect in reducing SARS-CoV-2-induced disease burden in mice. Our findings support the continued development of small-molecule entry inhibitors, alone or in combination with antibody-based therapies, as a promising strategy to counteract emerging SARS-CoV-2 variants. IMPORTANCE Mutations in the Spike glycoprotein drive viral evolution and confer resistance to current vaccines and some therapeutic interventions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report new analogs of the SARS-CoV-2 small-molecule entry inhibitor VE607. These analogs exhibited improved potency against emerging SARS-CoV-2 variants, including KP.3.1.1 and XEC. One analog, DY-III-281, delayed viral replication in SARS-CoV-2 WA1 -challenged K18-hACE2 transgenic mice, suggesting that small-molecule compounds targeting viral entry might be useful in fighting evolving SARS-CoV-2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche du CHUM, Montreal, Québec, Canada.
- Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Microbial Pathogenesis, Yale University, School of Medicine, New Haven, Connecticut, USA.
- Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Department of Microbiology, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Unit on Structural Biology, Division of Basic and Translational Biophysics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.
ORCID-Profile: Shilei Ding, Ling Niu, Monika Chandravanshi, William D Tolbert, James B Munro, Marzena Pazgier, Pradeep D Uchil, Andrés Finzi
Förderung
- CIHR operating Pandemic and Health Emergencies Research
- Division of Intramural Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH
- NIH HHS
- NIGMS NIH HHS
- CIHR
- Intramural NIH HHS
- Exceptional Fund COVID-19 from the Canada Foundation for Innovation
- NIAID NIH HHS
Zitieren
APA
Ding, S., Yang, D., Ullah, I., Niu, L., Unger, M., Díaz-Salinas, M. A., Chandravanshi, M., Zhou, F., Beaudoin-Bussières, G., Benlarbi, M., Tolbert, W. D., Yoon, K. W., Xu, R., Laroche, G., Gaudette, F., Morton, A. J., Lang, Z. C., Son, A., Abrams, C., …, & Finzi, A. (2025). Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants. Journal of Virology. https://doi.org/10.1128/jvi.01034-25
Vancouver
Ding S, Yang D, Ullah I, Niu L, Unger M, Díaz-Salinas MA, et al. Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants. Journal of Virology. 2025. doi:10.1128/jvi.01034-25
BibTeX
@article{Ding2025,
author = {Ding, Shilei and Yang, Derek and Ullah, Irfan and Niu, Ling and Unger, Matthew and Díaz-Salinas, Marco A and Chandravanshi, Monika and Zhou, Fei and Beaudoin-Bussières, Guillaume and Benlarbi, Mehdi and Tolbert, William D and Yoon, Keon-Woong and Xu, Ruixue and Laroche, Geneviève and Gaudette, Fleur and Morton, Abraham J and Lang, Zabrina C and Son, Anna and Abrams, Cameron and Côté, Marceline and Smith, Amos B and Huang, Rick K and Matthies, Doreen and Munro, James B and Pazgier, Marzena and Uchil, Pradeep D and Finzi, Andrés},
title = {Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01034-25}
}
EUVIMED